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Background
KS is a disease of multifocal vascular proliferation that
requires infection with the KS herpes virus (KSHV/
HHV-8). Activation of the c-kit and platelet derived
growth factor (PDGF) receptors by autocrine and para-
crine mechanisms follows KSHV infection of endothelial
cells. Partial KS regression in 5/10 patients was observed
in a pilot study using the c-kit/PDGF-R inhibitor imati-
nib (Novartis Pharmaceuticals), and 3/4 biopsies showed
PDGF inhibition, suggesting this agent has activity in
AIDS-related KS.
Methods
The primary objective was to estimate the response rate
of KS to imatinib in AIDS-related KS. Secondary objec-
tives included investigation of predictors of response
and imatinib pharmacokinetics in patients on cART.
Patients were treated with imatinib 400 mg/day orally
for up to 12 months with the option to dose escalate to
600 mg/day at 3 months if disease was stable. Plasma
concentrations of CCL5 (RANTES), IFNg, IL-6, and
FGF-b at baseline, day 8, and day 28 were measured
using the Mesoscale platform to assess the utility of
these growth factors as biomarkers.
Results
Thirty patients were treated at 12 AMC sites. Median
CD4 count was 263 (19-819). 79% had undetectable
HIV RNA. Ten (33.3%) showed partial response, 6
(20%) had stable disease, and 7 (23.3%) showed KS pro-
gression by modifed AIDS Clinical Trial Group response
criteria. Treatment was well tolerated. Nine patients
completed 52 weeks of imatinib and the median
treatment duration was 22.5 weeks (0.3-52.7). Only
5 patients (16.7%) discontinued therapy due to adverse
events including grade 3 hypophosphatemia (2), allergic
reaction (1), cellulitis (1), depression (1), and grade 4
elevation of CK (1). Pharmacokinetic analysis of the
AUC ratios (using day 1 and 15 sampling) demonstrated
that actual imatinib AUC levels were significantly higher
than predicted (P=0.036), but there was no difference
between actual and predicted AUC for the active meta-
bolite (P=0.441), suggesting the antiretroviral regimens
influenced imatinib metabolism. While baseline levels of
CCL5 and IFNg and changes in the levels of IL-6 and
FGF-b correlated with response in our pilot study, none
of these growth factors predicted response in this larger
study.
Conclusion
Imatinib has activity in AIDS-related Kaposi’s sarcoma.
The potential interactions with antiretroviral drugs did
not correlate with increased toxicity. Thirty percent of
patients showed long-term clinical benefit and remained
on imatinib for the entire year. These results suggest
this regimen is well tolerated and may be an alternative
to cytotoxic chemotherapy for some patients with
AIDS-related KS.
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